CognitiveResearch Phase

Galanin

Overview

Galanin is a 29 or 30 amino acid neuropeptide widely distributed throughout the central and peripheral nervous systems. It acts through three G protein-coupled receptor subtypes (GAL1, GAL2, and GAL3) to modulate neurotransmission, particularly in cholinergic, serotonergic, and noradrenergic pathways. The peptide has been implicated in cognitive processes, mood regulation, feeding behavior, and neuroprotection, making it a target of interest for neurodegenerative and psychiatric conditions.

Key Research Findings

Preclinical studies in rodent models have demonstrated that galanin modulates hippocampal acetylcholine release and affects performance in spatial learning tasks. Elevated galanin expression has been observed in postmortem brain tissue from patients with Alzheimer's disease, though the functional significance remains under investigation. No galanin-based therapeutics have advanced to late-stage clinical trials in cognitive disorders to date.

Route of Administration

Investigational

Regulatory Status

Research Phase

Interested in Galanin?

Find a verified provider experienced with Galanin protocols in your area. All providers are credentialed and use compliant sourcing.

Find a Galanin Provider

Related Peptides

Semax

FDA Approved

A synthetic heptapeptide analog of the ACTH(4-7) fragment (Met-Glu-His-Phe-Pro-Gly-Pro) with nootropic and neuroprotective properties. Semax modulates BDNF and NGF expression, enhances monoaminergic neurotransmission, and provides neuroprotection through anti-oxidant and anti-inflammatory mechanisms. It crosses the blood-brain barrier via intranasal administration.

Selank

Investigational

A synthetic analog of the endogenous tetrapeptide tuftsin (Thr-Lys-Pro-Arg) with an added Pro-Gly-Pro sequence for stability. Selank exhibits anxiolytic activity comparable to benzodiazepines without sedation, dependence, or withdrawal effects. It modulates the expression of BDNF, serotonin, dopamine, and norepinephrine, and influences IL-6 and GABA receptor expression.

Cerebrolysin

Investigational

A porcine brain-derived peptide preparation consisting of low-molecular-weight neuropeptides and free amino acids that mimic the action of endogenous neurotrophic factors. Cerebrolysin exhibits neurotrophic activity similar to BDNF, GDNF, and CNTF, promoting neuronal survival, synaptic plasticity, and neurogenesis. It modulates GSK-3beta, CDK5, and calcineurin-NFAT signaling cascades involved in neurodegeneration.

P21 (Peptide)

Research Phase

A small synthetic peptide derived from the active region of ciliary neurotrophic factor (CNTF) designed to promote neurogenesis and synaptic plasticity. P21 is a tetrapeptide that crosses the blood-brain barrier and enhances dentate gyrus neurogenesis by increasing BDNF expression. Unlike full-length CNTF, P21 does not activate the JAK-STAT pathway or produce the anorectic and immunogenic effects of the parent protein.